

InventisBio, Betta Pharma collaborate for Non-Small Cell Lung Cancer drug

28 December 2018 | News

The drug is currently in phase I clinical trial in China. Betta Pharma will pay upfront and R&D milestones to InventisBio totaling 230 million RMB.



InventisBio announced that it has signed a "Collaboration Agreement" with Betta Pharma. Under this agreement, InventisBio will out-license D-0316's right in China (including mainland China, Hong Kong and Taiwan) to Betta Pharma and to co-develop this drug in China.

Betta Pharma will have the exclusive commercialization rights of D-0316 product in China.

D-0316 is a third-generation EGFR-T790M tyrosine kinase inhibitor discovered and developed independently by InventisBio. It is mainly used for the treatment of EGFR-mutant non-small cell lung cancer. The drug is currently in phase I clinical trial in China. Betta Pharma will pay upfront and R&D milestones to InventisBio totaling 230 million RMB. After the product is marketed commercially, Betta Pharma will pay various sales milestones and tiered royalties based on annual sales.